Change in Preferred Hepatitis C Medication for Select Illinois Medicaid Members, Effective March 1, 2019

Posted March 6, 2019

Starting March 1, 2019, sofosbuvir/velpatasvir (the authorized generic of EPCLUSA®) will become the preferred combination hepatitis C product for Blue Cross and Blue Shield of Illinois (BCBSIL) members with Blue Cross Community Health PlansSM (BCCHPSM) prescription drug coverage.

  • BCCHP members who may be using other combination hepatitis C products now will be able to stay on their drug therapy. They will not need to make any changes.
  • Starting on or after March 1, 2019, patients not yet on a hepatitis C drug regimen will need to try our preferred agent, sofosbuvir/velpatasvir.

Please Note: In order for the pharmacy to give a member the generic of EPCLUSA, the prescription must be written for sofosbuvir/velpatasvir. The pharmacy cannot automatically switch to the generic if the brand name is written.

Members and providers may call the Member Services number on the member’s ID card for any questions about this change.

Trademarks are the property of their respective owners.

The above material is for informational purposes only and is not intended to be a substitute for the independent medical judgment of a physician. Physicians and other health care providers are encouraged to use their own best medical judgment based upon all available information and the condition of the patient in determining the best course of treatment.